Abstract
TTP is a type of thrombotic microangiopathy characterized by low platelets and evidence of a microangiopathic hemolytic anemia which produces platelet plugs and resultant red cell debris (called schistocytes). The underlying cause can be idiopathic or it can result from acquired antibodies to a protein called ADAMTS13 which serves to cleave von Willebrand multimers. TTP may also cause neurological abnormalities and less commonly renal failure. Definitive treatment is with plasmapheresis. It can cause a waxing and waning disease pattern. Untreated, the mortality is over 80%.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Kappler S, Ronan-Bentle S, Graham A. Thrombotic Microangiopathies (TTP, HUS, HELLP). Hematol Oncol Clin North Am. 2017;31:1081–103.
Reese JA, Muthurajah DS, Hovinga JAK, Vesely SK, Terrell DR, George JN. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013;60:1676–82.
Terrell DR, Vesely SK, Hovinga JAK, Lämmle B, George JN. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol. 2010;85:844–7.
Koyfman A, Brém E, Chiang VW. Thrombotic thrombocytopenic purpura. Pediatr Emerg Care. 2011;27:1085–8.
George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS registry, 1989–2007. Kidney Int. 2009; https://doi.org/10.1038/ki.2008.622.
Tsai H-M. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int. 2009; https://doi.org/10.1038/ki.2008.610.
Furlan M, Robles R, Galbusera M, et al. von Willebrand factor–cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic–uremic syndrome. N Engl J Med. 1998;339:1578–84.
Nokes T, George JN, Vesely SK, Awab A. Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. Eur J Haematol. 2013;92:156–63.
Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017;130(10):1181–8. https://doi.org/10.1182/blood-2017-04-636431.
Zakarija A, Kwaan HC, Moake JL, et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989–2008). Kidney Int. 2009; https://doi.org/10.1038/ki.2008.613.
Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura. Medicine. 1966;45:139–60.
Page EE, Hovinga JAK, Terrell DR, Vesely SK, George JN. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1:590–600.
George JN. Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why? Transfusion. 2015;55:11–3.
Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157.
Li A, Khalighi PR, Wu Q, Garcia DA. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost. 2017;16(1):164–9. https://doi.org/10.1111/jth.13882.
Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325:393–7.
Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009;53:259–72.
Scully M, Mcdonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746–53.
McClain RS, Terrell DR, Vesely SK, George JN. Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic syndrome: 2011 to 2014. Transfusion. 2014;54:3257–9.
Scully M. Trends in the diagnosis and management of TTP: European perspective. Transfus Apher Sci. 2014;51:11–4.
Swisher KK, Terrell DR, Vesely SK, Hovinga JAK, Lämmle B, George JN. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion. 2009;49:873–87.
Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019; [e-pub].; https://doi.org/10.1056/NEJMoa1806311.
Disclosure Statement
Joshua Faucher: No disclosures.
Colin Kaide: Callibra, Inc.-Discharge 123 medical software company. Medical Advisory Board Portola Pharmaceuticals. I have no relationship with a commercial company that has a direct financial interest in subject matter or materials discussed in article or with a company making a competing product.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Faucher, J., Kaide, C.G. (2020). Thrombotic Thrombocytopenia Purpura (TTP): “Who Are You Calling a FAT RN?” . In: Kaide, C., San Miguel, C. (eds) Case Studies in Emergency Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-22445-5_58
Download citation
DOI: https://doi.org/10.1007/978-3-030-22445-5_58
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-22444-8
Online ISBN: 978-3-030-22445-5
eBook Packages: MedicineMedicine (R0)